China is gradually becoming a
competitive force and evolving into the world’s fastest growing
market for In Vitro Diagnostics (IVD) products. By 2018 Chinese IVD
market with Billion US$ is expected to be twice more than from its
current market size in 2013. Immunoassay has the highest market share
compared to all other segments of In Vitro Diagnostics. Clinical
Chemistry is in the 2nd position, but its market share is declining
year on year, however its market is growing year on year. Molecular
Diagnostics holds the 3rd position and its market share is also
rising year on year. Roche holds the highest market share in China In
Vitro Diagnostics market.
View Full Report at
http://www.marketresearchreports.biz/analysis/235012
This is 3rd edition report on
In Vitro Diagnostics sector by Renub Research. Report titled “China
In Vitro Diagnostics (IVD) Market, Forecast & Companies Analysis”
provides a comprehensive assessment of the fast–evolving,
high–growth IVD Market in China. This 77 page report with 34
Figures studies the China IVD market from 4 view points:
- Market and Forecast
- Segment Wise Market & Forecast
- Development Environment & Regulatory Status in China IVD market
- Company Wise IVD Sales & Forecast
China
IVD Market – Application Segment Analysis (2007 – 2018)
- Clinical Chemistry Market
- Immunoassay Market
- Hematology Market
- Coagulation Market
- Microbiology Market
- Molecular Testing Market
- Self Monitoring of Blood Glucose (SMBG) Market
- Point of Care Testing (POCT) Market
Download Detail Report With
Complete TOC at
http://www.marketresearchreports.biz/sample/sample/235012
China IVD – Company Wise
Sales Analysis (2010 – 2018)
- Roche Diagnostic
- Sysmex Corporation
- Mindray Medical International Limited
- Shanghai Kehua Bio–Engineering Co. Ltd.
- Others
Profiles
of Private Clinical Labs and Diagnostic Services Companies in China
- Zhejiang Di’an Diagnostics Technology Co., Ltd
- ADICON Clinical Laboratories
- Guangzhou Kingmed Diagnostics Center Co. Ltd.
- Kindstar Global (Privately held)
- BGI–Shenzhen (Privately held)
- OriGene Technologies (Privately held)
No comments:
Post a Comment